XML 85 R40.htm IDEA: XBRL DOCUMENT
v3.24.1

Business Combination (Details) - USD ($) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 10, 2022 | Oct. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Aug. 03, 2022 | Jul. 29, 2022 | Jul. 11, 2022 | Oct. 15, 2018
Business Combination |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  | 17,868,282 | 15,844,061 | 17,868,282 | 15,844,061 |  | 2,459,016 |  |
Common stock, price per share |  |  | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 |  | $ 0.001 | $ 1,000
Fair value adjustment decrease to contingent consideration |  |  |  |  | $ (660,000) | $ 2,091,000 |  |  |  |
V C N |  |  |  |  |  |  |  |  |  |
Business Combination |  |  |  |  |  |  |  |  |  |
Common stock, shares issued | 2,639,530 |  |  |  |  |  |  |  |  |
Amount to be paid due to approval |  |  |  | $ 3,000,000.0 |  |  |  |  |  |
Payment made after clinical trial |  | $ 3,250,000 |  |  |  |  |  |  |  |
Finance costs | $ 417,000 |  |  |  |  |  |  |  |  |
Fair value of contingent consideration | 11,093,000 |  | $ 6,300,000 | $ 10,200,000 | $ 6,300,000 | $ 10,200,000 |  |  |  |
Purchase consideration | 22,809,000 |  |  |  |  |  |  |  |  |
V C N | General and administrative expenses |  |  |  |  |  |  |  |  |  |
Business Combination |  |  |  |  |  |  |  |  |  |
Fair value of contingent consideration | 27,800,000 |  |  |  |  |  |  |  |  |
V C N | Grifols Innovation |  |  |  |  |  |  |  |  |  |
Business Combination |  |  |  |  |  |  |  |  |  |
Consideration purchase paid | $ 4,700,000 |  |  |  |  |  |  |  |  |
Common stock, price per share | $ 0.001 |  |  |  |  |  |  |  |  |
Existing liabilities | $ 2,390,000 |  |  |  |  |  |  |  |  |
Cash payments | $ 70,200,000 |  |  |  |  |  |  |  |  |
Payment made after clinical trial |  |  | $ 3,250,000 |  |  |  |  |  |  |
V C N | New technologies |  |  |  |  |  |  |  |  |  |
Business Combination |  |  |  |  |  |  |  |  |  |
Business acquisition, percentage of voting interests acquired | 86.00% |  |  |  |  |  |  |  |  |

X
- Definition Amount paid due to approval. + References No definition available. + Details
Name: | tovx_AmountToBePaidDueToApproval
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cash payments. + References No definition available. + Details
Name: | tovx_CashPayments
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of cash payments existing liabilities. + References No definition available. + Details
Name: | tovx_CashPaymentsExistingLiabilities
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of closing financing costs. + References No definition available. + Details
Name: | tovx_ClosingFinanceCosts
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration for the purchase paid. + References No definition available. + Details
Name: | tovx_ConsiderationPurchasePaid
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments to be made after initiating patient dosing in the US and phase 2 clinical trial. + References No definition available. + Details
Name: | tovx_PaymentMadeAfterClinicalTrial
Namespace Prefix: | tovx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tovx_VCNBiosciencesS.LMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=tovx_GrifolsInnovationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=tovx_NewTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |